Brief: Matinas Biopharma - remains in discussions with Biontech for option to license lnc platform for MRNA on an exclusive basis
11/08/2022 11:31
Aug 11 (Reuters) - Matinas BioPharma Holdings Inc MTNB.A :
* MATINAS BIOPHARMA - REMAINS IN DISCUSSIONS WITH BIONTECH
FOR
OPTION TO LICENSE LNC PLATFORM FOR MRNA ON AN EXCLUSIVE BASIS
* MATINAS BIOPHARMA - BELIEVES CASH ON HAND IS SUFFICIENT TO
FUND
PLANNED OPERATIONS THROUGH 2023
* MATINAS BIOPHARMA HOLDINGS INC QTRLY NET LOSS OF $0.03
PER
SHARE (BASIC AND DILUTED)
Further company coverage: MTNB.A
Recent news on Matinas BioPharma Holdings
See all newsBrief: GH Power Signs Multi-Year Hydrogen Offtake Agreement With Change Energy For Hamilton Facility Output
Brief: Gh Power And Tkms Continue To Explore Clean Energy Collaboration In Support Of Canada’S Future Patrol Submarine Project
Brief: Matinas Biopharma - Btig Terminates Sales Agreement With Matinas Biopharma Holdings, Effective Immediately On July 23, 2026 - SEC Filing
Brief: Matinas Biopharma Receives Notice Of Non-Compliance With NYSE American Continued Listing Standards And Acceptance Of Plan To Regain Compliance
Brief: Matinas Biopharma - May Offer Securities Up To $150 Million - SEC Filing